Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Pittsburgh, Pennsylvania 15213


Purpose:

Phase I trial to study the effectiveness of interleukin-12 in treating patients with refractory ovarian or abdominal cancers. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a persons's white blood cells to kill cancer cells.


Study summary:

OBJECTIVES: I. Assess the safety and maximum tolerated dose of recombinant human interleukin-12 (rhIL-12) administered by intraperitoneal infusion in patients with chemotherapy refractory advanced ovarian cancer and other diffuse abdominal carcinomatosis. II. Determine the immunopharmacologic profile of rhIL-12 in this patient population. III. Evaluate the biologic response in selected patients to rhIL-12 administered through intraperitoneal infusions. OUTLINE: This is a dose escalation, multicenter study. Cohorts of 3-6 patients each receive escalating doses of intraperitoneal recombinant human interleukin-12 (rhIL-12) administered weekly for 9 weeks. If a patient tolerates rhIL-12 and shows evidence of objective response or stable disease, patient may receive up to 9 additional weeks of treatment. Treatment continues in the absence of unacceptable toxicity or disease progression. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which no more than 1 of 6 patients experiences dose limiting toxicity. All patients are followed for survival.


Criteria:

DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed intraabdominal cancer - Diffuse abdominal carcinomatosis Chemotherapy refractory advanced stage ovarian cancer - Measurable disease - Residual, recurrent, or metastatic disease beyond the scope of standard curative therapy - Extension of disease to sites distant to the peritoneal cavity allowed Retroperitoneal lymphadenopathy allowed as long as there is evaluable intraabdominal disease - No history of progressive brain metastases PATIENT CHARACTERISTICS: - Age: 18 and over - Performance status: Karnofsky 70-100% - Hemoglobin greater than 9 g/dL - WBC greater than 3,000/mm3 - Platelet count greater than 100,000/mm3 - Bilirubin less than 2.0 mg/dL - ALT less than 100 U/L - Creatinine clearance greater than 60 mL/min - Normal electrocardiogram - No recent history of cardiac ischemia - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Hepatitis B negative - No evidence of clinical immunodeficiency syndromes or immunodeficiency associated diseases - No history of autoimmune disease - No concurrent major illness - No serious infection requiring intravenous antibiotics - No active peptic ulcer disease - Must have free flow of fluid into the peritoneal space - No leakage from the catheter exit site PRIOR CONCURRENT THERAPY: - At least 3 weeks since prior biologic therapy (6 weeks for interleukin-2) - No prior recombinant human interleukin-12 - At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) - No concurrent systemic chemotherapy - No concurrent systemic corticosteroids - No prior radiation therapy to the whole abdomen - No concurrent radiotherapy - At least 3 weeks since prior exposure to any investigational drug - No concurrent investigational drug


NCT ID:

NCT00003439


Primary Contact:

Study Chair
Robert P. Edwards, MD
University of Pittsburgh


Backup Contact:

N/A


Location Contact:

Pittsburgh, Pennsylvania 15213
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 24, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.